Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) has issued an announcement.
Ab&B Bio-Tech CO., LTD. JS has announced the current composition of its board of directors, comprising three executive directors, three non-executive directors, and three independent non-executive directors, with An Youcai serving as chairman. The company also detailed the membership and chairpersonship of its four key board committees covering audit, remuneration and appraisal, nomination, and strategy, reinforcing its governance framework and oversight structure for investors and other stakeholders.
The audit committee is chaired by independent director Li Jianjun, while the remuneration and appraisal committee and the nomination committee are chaired by independent director Chen Chengbei, and the strategy committee is led by chairman An Youcai, indicating a mix of executive and independent oversight across core governance functions. By clearly allocating committee responsibilities among executive, non-executive, and independent non-executive directors, Ab&B Bio-Tech aims to enhance transparency, checks and balances, and strategic supervision in line with Hong Kong market expectations for listed companies.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2627. The company operates in the biotechnology sector, though this announcement focuses solely on its corporate governance structure rather than its specific products, services, or market segments.
Average Trading Volume: 740,312
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.54B
Find detailed analytics on 2627 stock on TipRanks’ Stock Analysis page.